Way oversold! On the 4hr chart, it's trapped in a falling wedge and will likely breakout to the upside. SSE Composite is finding a short term bottom and US markets also seem to be turning bullish for short term. BABA will have some support for a move higher.
Target 1: $71
Target 2: 50dma or $73.50 - $74 (whichever is closest resistance at the time)
Think there...
- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2...
Doctors around the world have been using Stereotaxis' revolutionary technology for heart surgeries and have given positive feedback. Many more applications coming- using the same systems. With the right marketing team this company should grow quickly over the next few years.
It's been in an uptrend since late 2014 and is currently at support. This entry around...
Earnings estimates have come down over the last few weeks.
Rev Estimates = 2.78 billion
EPS Estimates = .43
Based on previous financials, it's likely going to beat revenue estimates and maybe EPS estimates.
Price Target: $95
